

**Claims**

1. A process to minimise loss of one or more of the components through adhesion to equipment surfaces, which comprises addition of two or more components to a container in a stepwise manner.  
5
2. A process for adding components to a multicomponent pharmaceutical formulation for inhalation comprising a step wise addition of the components to a container in order to minimize or eradicate losses due to adhesion of component to the  
10 container surface.
3. A process according to claim 1 or 2 in which the component of largest mass is added first.  
15
4. A process according to claim 2 or 3 in which the formulation components are active drug substances.  
20
5. A process according to any one of claims 2 to 4 in which the formulation is for a pressurized metered dose inhaler.
6. A process according to claim 4 or 5 in which the active drug substances are budesonide and formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.  
25
7. A process according to any one of claims 4 to 6 in which the active drug substances are budesonide and formoterol fumarate dihydrate.  
30
8. A process according to claim 7 in which the molar ratio of the budesonide to the formoterol fumarate dihydrate is from 2500:1 to 1:1.
9. A pharmaceutical formulation prepared according to the process defined in any one of claims 2 to 8.  
35
10. A formulation according to claim 9 which is in the form of a suspension.

11. A formulation according to claim 10 in which the drugs are suspended in one or more HFA propellants.
12. A formulation according to claim 11 in which the HFA propellants are HFA 134a or  
5 HFA 227 or a mixture thereof.
13. Use of a formulation according to any one of claims 9 to 12 for the treatment or prophylaxis of asthma or COPD.
- 10 14. A method of treating asthma or COPD which comprised administering to a patient in need of such treatment a formulation according to any one of claims 9 to 12.